H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Viking Therapeutics to $33 from $21 and keeps a Buy rating on the shares post the Q1 results. The company ended the quarter in a financially strong position, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VKTX:
- Viking Therapeutics reports Q1 EPS (25c), consensus (24c)
- Viking Therapeutics price target raised to $35 from $30 at Oppenheimer
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics 17.242M share Spot Secondary priced at $14.50
- Viking Therapeutics Spot Secondary; price range $14.50-$15.00
